Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hoffmann

Showing results (251-260 of 312) with videos related to

Pageof 32
Sort By:
The Journal of Biological Chemistry|September 12, 2020
Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2Michael J Edwards, Katrin Anne Becker, Barbara Gripp, et al.
International Journal of Oncology|October 14, 2014
Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in GermanyElgar Susanne Quabius, Jochen Haag, André Kühnel, et al.
Ebiomedicine|December 20, 2021
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variantsRüdiger Groß, Michelle Zanoni, Alina Seidel, et al.
Frontiers in Immunology|August 12, 2022
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adultsAlina Seidel, Michelle Zanoni, Rüdiger Groß, et al.
The Lancet. Infectious Diseases|April 15, 2022
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3Prerna Arora, Lu Zhang, Cheila Rocha, et al.
Viruses|January 8, 2025
Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant RecipientsPhilippa von der Schulenburg, Georg M N Behrens, Markus Hoffmann, et al.
Plos Pathogens|November 13, 2024
ACE2-independent sarbecovirus cell entry can be supported by TMPRSS2-related enzymes and can reduce sensitivity to antibody-mediated neutralizationLu Zhang, Hsiu-Hsin Cheng, Nadine Krüger, et al.
Cell|April 1, 2021
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodiesMarkus Hoffmann, Prerna Arora, Rüdiger Groß, et al.
The Journal of Infection|July 5, 2023
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trialChristian Taucher, Rajeka Lazarus, Hanna Dellago, et al.
Journal of the American Chemical Society|September 24, 2011
Belt-shaped π-systems: relating geometry to electronic structure in a six-porphyrin nanoringJohannes K Sprafke, Dmitry V Kondratuk, Michael Wykes, et al.
Pageof 32

Showing results (251-260 of 312) with videos related to

Sort By:
Pageof 32
The Journal of Biological Chemistry|September 12, 2020
Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2Michael J Edwards, Katrin Anne Becker, Barbara Gripp, et al.
International Journal of Oncology|October 14, 2014
Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in GermanyElgar Susanne Quabius, Jochen Haag, André Kühnel, et al.
Ebiomedicine|December 20, 2021
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variantsRüdiger Groß, Michelle Zanoni, Alina Seidel, et al.
Frontiers in Immunology|August 12, 2022
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adultsAlina Seidel, Michelle Zanoni, Rüdiger Groß, et al.
The Lancet. Infectious Diseases|April 15, 2022
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3Prerna Arora, Lu Zhang, Cheila Rocha, et al.
Viruses|January 8, 2025
Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant RecipientsPhilippa von der Schulenburg, Georg M N Behrens, Markus Hoffmann, et al.
Plos Pathogens|November 13, 2024
ACE2-independent sarbecovirus cell entry can be supported by TMPRSS2-related enzymes and can reduce sensitivity to antibody-mediated neutralizationLu Zhang, Hsiu-Hsin Cheng, Nadine Krüger, et al.
Cell|April 1, 2021
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodiesMarkus Hoffmann, Prerna Arora, Rüdiger Groß, et al.
The Journal of Infection|July 5, 2023
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trialChristian Taucher, Rajeka Lazarus, Hanna Dellago, et al.
Journal of the American Chemical Society|September 24, 2011
Belt-shaped π-systems: relating geometry to electronic structure in a six-porphyrin nanoringJohannes K Sprafke, Dmitry V Kondratuk, Michael Wykes, et al.
Pageof 32